View Older Stories View More Recent Stories

Jan 29, 2019 04:30PM Mary Ellen Coe Elected to Merck Board of Directors
Jan 29, 2019 03:08PM Merck Announces Second-Quarter 2019 Dividend
Jan 22, 2019 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2018 Sales and Earnings Conference Call on February 1
Jan 14, 2019 05:01PM Merck's (MRK) KEYTRUDA Reduced Risk of Death by 31% Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma
Jan 14, 2019 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tu
Jan 3, 2019 06:53AM Merck (MRK) Announces Five New Approvals for KEYTRUDA (pembrolizumab) in Japan, Including 3 Expanded Uses in Advanced NSCLC
Jan 3, 2019 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite In
Jan 3, 2019 06:34AM Merck (MRK) Exercises Option to License NGM313, for Treatment of NASH & Type 2 Diabetes
Jan 3, 2019 06:30AM Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes
Jan 2, 2019 06:45AM Merck to Participate at the 37th Annual J.P. Morgan Healthcare Conference
Dec 21, 2018 02:06PM UPDATE: Merck KGaA, Pfizer (PFE) to Terminate JAVELIN Ovarian 100 Trial of Avelumab
Dec 21, 2018 02:00PM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
Dec 20, 2018 04:27PM Merck (MRK) Reports Extended Action Date on KEYTRUDA (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial
Dec 20, 2018 04:15PM Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial
Dec 20, 2018 06:31AM Merck (MRK) Reports LYNPARZA (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer
Dec 20, 2018 06:30AM LYNPARZA® (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer
Dec 19, 2018 04:13PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer
Dec 19, 2018 04:04PM AstraZeneca (AZN) and Merck (MRK) Reports LYNPARZA Approved by FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer
Dec 19, 2018 03:18PM Merck (MRK) Announces LYNPARZA Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
Dec 19, 2018 03:16PM LYNPARZA® (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
Dec 17, 2018 06:31AM Merck (MRK) Announces EC Approves its KEYTRUDA as Adjuvant Therapy for Adults with Resected Stage III Melanoma
Dec 17, 2018 06:30AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma
Dec 14, 2018 06:46AM Merck (MRK) to Acquire Antelliq Group for EUR2.1 Billion Plus Debt
Dec 14, 2018 06:45AM Merck to Acquire Privately Held Antelliq Group
Dec 12, 2018 10:30AM Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections
Dec 10, 2018 04:30PM Merck’s President of Global Human Health Adam H. Schechter to Leave Merck Frank Clyburn Named Chief Commercial Officer and Michael Nally Named Chief Marketing Officer
Dec 10, 2018 11:30AM MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models
Dec 3, 2018 06:45AM Merck to Present at the Citi 2018 Global Healthcare Conference
Nov 28, 2018 04:32PM Merck (MRK) says EC Approved DELSTRIGO and PIFELTRO for Treatment of HIV-1 Infection
Nov 28, 2018 04:30PM European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravir
Nov 27, 2018 08:00AM MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018
Nov 19, 2018 07:12AM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Nov 15, 2018 09:01AM NewLink Genetics (NLNK) Says Merck (MRK) Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 to FDA
Nov 14, 2018 06:51AM Merck (MRK) Reports Phase 3 KEYNOTE-181 Trial Investigating KEYTRUDA Met a Primary Endpoint of OS in Patients Whose Tumors Express PD-L1
Nov 14, 2018 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expre
Nov 13, 2018 04:36PM Merck (MRK) Begins Rolling Submission of Licensure Application for V920 to FDA
Nov 13, 2018 04:35PM Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
Nov 12, 2018 06:56AM Merck (MRK) Says FDA Accepted Regulatory Submission for LYNPARZA Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review
Nov 12, 2018 06:55AM FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review
Nov 9, 2018 04:22PM Merck (MRK) Announces FDA Approval of KEYTRUDA for Treatment of Patients with HCC Who Have Been Previously Treated with Sorafenib
Nov 9, 2018 04:21PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
Nov 9, 2018 06:47AM Eisai and Merck (MRK) Announces New Data from Study of LENVIMA and KEYTRUDA Combination in Three Different Tumor Types
Nov 9, 2018 06:45AM New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd An
Nov 7, 2018 06:55AM Merck (MRK) Says Early Phase 1 Data from Oncology Pipeline for Investigational Anti-LAG-3 Therapy and Anti-TIGIT Therapy to Be Presented at SITC
Nov 7, 2018 06:45AM Early Phase 1 Data from Merck’s Oncology Pipeline for Investigational Anti-LAG-3 Therapy (MK-4280) and Anti-TIGIT Therapy (MK-7684) to Be Presented at SITC’s 33rd Annual Meeting
Nov 5, 2018 10:00AM MilliporeSigma Launches BioContinuum™ Platform for Next-Generation Process Improvements
Nov 1, 2018 07:11AM From pharma to prisons, election-sensitive stocks that could swing
Oct 30, 2018 05:01PM Merck (MRK) Says FDA Approved its KEYTRUDA in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for Patients with NSCLC
Oct 30, 2018 04:09PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Ce
Oct 25, 2018 06:46AM Merck Announces Increased Fourth-Quarter Dividend and $10 Billion Share Repurchase Authorization
View More Recent Stories View Older Stories